Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients
Table 1
Baseline clinical and histological characteristics of the HER2− patients.
Number
Age
Clinical stage
TNM staging
Nottingham score
Menopause age
ER/PR status
1
58
II B
T2N1M0
II
#
ER−/PR−
2
53
III A
T2N2M0
II
50
ER−/PR−
3
40
III B
T4bN2M0
II
39
ER−/PR−
4
45
III A
T3N1M0
III
#
ER−/PR−
5
48
II B (R)/I A (L)
T2N1M0(R)/T1N0M0(L)
III
32
ER−/PR−
6
49
II B
T2N1M0
III
#
ER−/PR−
7
50
III B
T4bN1M0
II
#
ER−/PR−
8
55
III B (R)/I B (L)
T4bN2M0(R)/T1N0M0 (L)
III
51
ER−/PR−
9
56
II B
T2N1M0
III
N/A
ER−/PR−
10
60
II A
T1N1MO
III
45
ER−/PR−
11
35
II B
T2N1M0
III
#
ER−/PR−
12
53
III A
T2N2M0
III
50
ER−/PR−
13
40
II B
T2N1M0
III
#
ER−/PR−
14
74
III B
T4bN2M0
III
48
ER−/PR−
15
50
II B
T2N1M0
II
50
ER+/PR+
16
45
II B
T2N1M0
I
45
ER+/PR+
17
52
III A
T2N2M0
III
N/A
ER+/PR+
18
54
III A
T2N2M0
II
#
ER+/PR+
19
65
III B
T4bN2M0
II
47
ER+/PR+
20
50
I
T1cN0M0
III
45
ER+/PR+
21
62
III B
T4bN2M0
II
54
ER+/PR+
22
52
III B
T4bN2M0
III
50
ER+/PR+
23
62
III A
T3N1M0
II
52
ER+/PR+
24
68
II B
T3N0M0
I
50
ER+/PR+
25
49
III A
T3N1M0
I
#
ER+/PR+
26
43
III A
T3N1M0
I
44
ER+/PR+
27
63
III B
T4aN0M0
II
40
ER+/PR+
28
52
II B
T2N1M0
II
52
ER+/PR+
29
48
II A
T2N0M0
II
#
ER+/PR+
Patients with bilateral breast cancer: R, right breast tumor; L, left breast tumor. #: the patient has been diagnosed before reaching menopause; N/A: missing data.
